Prediction: New Reason Lilly Stock Could Still Rise
Eli Lilly stock could advance in the second half of 2026 as Foundayo gains traction and the GLP-1 franchise shines, b...
Foundayo
3 articles
Wegovy Pill Still Dominating GLP-1 Market, Analysts Say
Wegovy continues to lead the U.S. GLP-1 market despite Eli Lilly's Foundayo launch. Investors are weighing uptake, pa...
CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...